Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2009

01-02-2009 | Original Article

Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer

Authors: Hee Man Kim, Seungmin Bang, Jeong Youp Park, Jinsil Seong, Si Young Song, Jae Bock Chung, Seung Woo Park

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2009

Login to get access

Abstract

Purpose

S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.

Methods

Eligibility criteria were histologically proven pancreatic adenocarcinoma, locally advanced disease, and no previous treatment. S-1 was administered orally at a dose of 40 mg/m2 twice daily from day 1 to 14 and from day 22 to 35, and concurrent radiotherapy (a total dose of 50.4 Gy) was delivered in 28 fractions. One month after treatment completion, tumor response was evaluated by computed tomography (CT).

Results

A total of 25 patients were evaluable for efficacy and toxicity on the basis of the intention-to-treat analysis. The response rate and disease control rate were 24.0 and 68.0%, respectively. There was no treatment-related death or grade 4 toxicity. The most common grade 3 hematologic and non-hematologic toxicities were thrombocytopenia (4.0%) and anorexia (20%), respectively. All toxicities were tolerable and transient. The median time-to-progression and median overall survival were 6.5 months (95% confidence interval, 4.1–9.0 months) and 12.9 months (95% confidence interval, 6.7–19.0 months), respectively, and the 1-year survival rate was estimated to be 43%.

Conclusions

S-1 and concurrent radiotherapy shows favorable efficacy for disease control against locally advanced pancreatic cancer and was well tolerated with no severe toxicities.
Literature
1.
A’Hern RP (2001) Sample size table for exact single-stage phase II designs. Stat Med 20:859–866PubMedCrossRef
2.
Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, Song SY (2006) The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40:923–929PubMedCrossRef
3.
Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed
4.
Choi HJ, Kim NK, Keum KC, Cheon SH, Shin SJ, Baik SH, Choen JH, Rha SY, Roh JK, Jeung HC, Chung HC, Ahn JB (2008) Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. Radiother Oncol 87:361–366PubMedCrossRef
5.
Crane CH, Varadhachary G, Pisters PWT, Evans DB, Wolff RA (2007) Future chemoradiation strategies in pancreatic cancer. Semin Oncol 34:335–346PubMedCrossRef
6.
Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radioatherapy) to chemotherapy alone. J Natl Cancer Inst 80:751–755CrossRef
7.
Harada K, Ferdous T, Yoshida H (2007) Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma. Oncol Rep 18:1077–1083PubMed
8.
Harada K, Kawaguchi S, Supriatno , Kawashima Y, Yoshida H, Sato M (2005) S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett 226:161–168PubMedCrossRef
9.
Harada K, Kawaguchi S, Supriatno , Onoue T, Yoshida H, Sato M (2004) Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 40:713–719PubMedCrossRef
10.
Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1995) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000–2005
11.
Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331PubMedCrossRef
12.
Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse F, Ishii H, Kawashima M, Kagami Y, Ikeda H (2007) A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer 96:1650–1655PubMedCrossRef
13.
Ishii H, Furuse J, Nakachi K, Suzuki E, Yoshino M (2005) Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials. Jpn J Clin Oncol 35:601–606PubMedCrossRef
14.
Kim R, Saif MW (2007) Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? J Pancreas 8:279–288
15.
Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, Tanigawa T, Yamamoto H, Kurokawa E (2003) A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 6(Suppl 1):34–39PubMedCrossRef
16.
Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378PubMed
17.
Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867–872PubMed
18.
Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867PubMedCrossRef
19.
Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710PubMedCrossRef
20.
Moureau-Zabotto L, Phélip JM, Afchain P, Mineur L, André T, Vendrely V, Lledo G, Dupuis O, Huguet F, Touboul E, Balosso J, Louvet C (2008) Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol 26:1080–1085PubMedCrossRef
21.
Nakata E, Fukushima M, Takai Y, Nemoto K, Ogawa Y, Nomiya T, Nakamura Y, Milas L, Yamada S (2006) S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU. Oncol Rep 16:465–471PubMed
22.
Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83:141–145PubMedCrossRef
23.
Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615–621PubMedCrossRef
24.
Oya N (2004) Chemoradiotherapy for pancreatic cancer: current status and perspectives. Int J Clin Oncol 9:451–457PubMedCrossRef
25.
Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2008) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 99:6–13PubMedCrossRef
26.
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720PubMedCrossRef
27.
Shinchi H, Maemura K, Noma H, Mataki Y, Aikou T, Takao S (2007) Phase-I trial of oral fluoropyridine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. Br J Cancer 96:1353–1357PubMed
28.
Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotocitiy of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557PubMedCrossRef
29.
Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Akihiko N, Kawakami H, Uno T, Ito H, Saisho H (2007) Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiation Oncology Biol Phys 67:219–224
30.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
31.
Tsuji H, Kiba T, Nagata M, Inoue T, Yukawa H, Yamashita T, Shimode Y, Murata H, Nagata K, Tomoda K (2006) A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. Oncology 71:369–373PubMedCrossRef
32.
Ueno H, Okusaka T, Ikeda M, Takezako Y (2005) An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68:171–178PubMedCrossRef
Metadata
Title
Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer
Authors
Hee Man Kim
Seungmin Bang
Jeong Youp Park
Jinsil Seong
Si Young Song
Jae Bock Chung
Seung Woo Park
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0836-1

Other articles of this Issue 3/2009

Cancer Chemotherapy and Pharmacology 3/2009 Go to the issue

Erratum

Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

Original Article

Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer

Short Communication

Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

Original Article

A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state

Original Article

ASNA1, an ATPase targeting tail-anchored proteins, regulates melanoma cell growth and sensitivity to cisplatin and arsenite

Original Article

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits